Introduction {#s0001}
============

Low-grade persistent inflammation is involved in the initiation and progression of age-related diseases.[@cit0001] The individual risk of developing inflammation-related diseases clearly varies due to genetic and environmental differences. The diet is an important factor influencing the immune system, and a diet rich in marine n-3 PUFAs possesses anti-inflammatory properties. Beneficial effects of n-3 PUFAs involve a changed membrane lipid composition and the promoted synthesis of anti-inflammatory and pro-resolving eicosanoids.[@cit0002] Also, regulatory signaling by n-3 PUFAs has been reported via, among others, the selective FFAR4/GPR120 (free fatty acid receptor 4) protein leading to reduced activity of the NFKB (nuclear factor kappa B) complex and the inflammasome.[@cit0003]

Macroautophagy (hereafter referred to as autophagy) is a catabolic process that eliminates damaged and excessive intracellular components by lysosomal degradation.[@cit0006] Cytoplasmic proteins and organelles are sequestered by a growing double membrane that forms an autophagosomal vesicle where the content is degraded after fusion with a lysosome.[@cit0007] The autophagic receptor SQSTM1 binds to ubiquitinated cargos and interacts with mammalian orthologs of yeast *ATG8* (autophagy-related 8) on the growing phagophore membrane leading to selective degradation.[@cit0008]

Homopolymerization of SQSTM1 is important for efficient sequestration and turnover of cargo.[@cit0009] In the case of altered protein degradation or in response to cellular stresses, the accumulation of SQSTM1 in ubiquitin (Ub)-positive so-called SQSTM1/p62-bodies (also known as aggresome-like induced structures \[ALIS\]) has been described and might provide a temporary form of storage for unfolded proteins to be destroyed.[@cit0010] Autophagy is important to prevent inflammation-prone conditions by maintaining cellular homeostasis but also directly by selective elimination of invading pathogens (xenophagy)[@cit0011] and the removal of activated inflammasomes.[@cit0014]

As for autophagic removal of cargo, several inflammatory responses depend on ubiquitination for complex formation, activation or degradation of the signaling proteins.[@cit0017] Interestingly, SQSTM1 can also have a pro-inflammatory role as its ubiquitin-binding and polymerizing abilities are necessary for NF-kB complex activation, suggesting a scaffold function in the formation of signaling complexes.[@cit0018]^,^[@cit0019]

We recently reported that physiologically relevant doses of the n-3 PUFA DHA elevates levels and cytosolic structures of SQSTM1 and increases turnover of polyubiquitinated proteins in retinal pigment epithelium cells (ARPE-19), possibly reducing the risk of age-related macular degeneration.[@cit0020] We thus hypothesized that n-3 PUFAs affect autophagy or ubiquitination to mobilize an anti-inflammatory effect in macrophages. We here report that human primary monocyte-derived macrophages (MDM) and RAW264.7 mouse macrophages respond to n-3 PUFAs by induction of *SQSTM1* mRNA and protein levels followed by a transient rise in the number of ALIS like SQSTM1/p62-bodies. While SQSTM1/p62-bodies are present, there is a clearly dampened response to lipopolysaccharide (LPS), particularly by a reduced IFN (interferon) type-I response. Consistently, the reduced secretion of the IFN response protein CXCL10 is evident both in macrophage cell cultures and in blood samples from patients on n-3 PUFA supplements.

Results {#s0002}
=======

The n-3 PUFA DHA induces SQSTM1/p62-bodies in macrophages {#s0002-0001}
---------------------------------------------------------

To determine if n-3 PUFAs affect localization of SQSTM1 and ubiquitinated proteins in macrophages, RAW264.7 cells were supplemented with 70 µM of the n-3 PUFA DHA, the n-6 PUFA arachidonic acid (AA) or the n-9 monounsaturated fatty acid oleic acid (OA). The cells were immunostained for SQSTM1 and conjugated Ub. Confocal inspection showed formation of SQSTM1/p62-bodies in response to DHA in a lipid-selective manner. Further, the DHA-induced \\SQSTM1/p62-bodies colocalized more stringently with ubiquitinated proteins ([Fig. 1A](#f0001){ref-type="fig"}) than with MAP1LC3B (microtubule associated protein 1 light chain 3 β; data not shown), thus representing aggregates rather than autophagosomes. The number of SQSTM1/p62-bodies and colocalization with Ub transiently increased up to 16 h and decayed to basal levels after 24 h ([Fig. 1B](#f0001){ref-type="fig"}). Consistently, the level of SQSTM1 and Ub-conjugated proteins also rose in response to DHA supplementation in RAW264.7 cells in a time- and concentration-dependent manner ([Fig. 1C](#f0001){ref-type="fig"}, S1A and S1B). Figure 1.The n-3 PUFA DHA induces SQSTM1/p62-bodies in macrophages. (A) Confocal analysis of RAW264.7 cells treated with DHA, OA or AA (70 µM) for 8 h (scale bars: 10 µm) and (B) automated quantification of SQSTM1- and Ub-positive speckles (\< 7000 cells/condition). Data are representative of 3 independent experiments of which 2 were manually counted. (C) Immunoblot (IB) analysis and quantification (below) of RAW264.7 cells treated with DHA, OA and AA (70 µM) for 16 h, n = 4, (repeated measures ANOVA with Dunnett\'s). (D) Confocal analysis of MDMs treated with DHA, OA or AA (70 µM) for 24 h (scale bars: 10 µm) and (E) automated quantification of SQSTM1/p62-bodies (\< 4000 cells/condition), n = 3 except for 48 h where n = 1. (F) IB and quantification (below) of MDMs treated with DHA, OA and AA (70 µM) for 16 h, n = 5, (Friedman test with Dunn\'s).

Human primary MDM displayed the same lipid-specific increase in SQSTM1/p62-bodies and colocalized ubiquitin after DHA supplementation ([Fig. 1D](#f0001){ref-type="fig"}). Automated image analysis demonstrated that the average number of SQSTM1/p62-bodies increased up to 24 h after DHA supplementation and decreased thereafter ([Fig. 1E](#f0001){ref-type="fig"}), thus showing the same transient rise although at a slightly slower kinetics compared to the mouse macrophages. MDMs similarly demonstrated a selective increase in the protein levels of SQSTM1 and conjugated Ub in response to DHA, whereas no increase was observed after treatment with OA or AA ([Fig. 1F](#f0001){ref-type="fig"}). Interestingly, the increase in protein level of SQSTM1 was observed already after 6 h treatment with DHA and was further increased with time up to 24 h (Fig. S1C).

DHA induces formation of detergent-resistant SQSTM1/p62-bodies degraded by autophagy and activates NFE2L2 {#s0002-0002}
---------------------------------------------------------------------------------------------------------

DHA supplementation caused a striking translocation of SQSTM1 from a mainly diffuse cytoplasmic location into cytoplasmic bodies associated with ubiquitinated proteins. Such protein deposits or ALIS tend to be resistant to detergents.[@cit0021]^,^[@cit0022] To determine if DHA-induced SQSTM1/p62-bodies were detergent resistant, the pellets that remained after centrifugation in a detergent lysis buffer were resolved in 8 M urea buffer. Interestingly, the protein level of SQSTM1 in the detergent-resistant pellet was clearly elevated after DHA supplementation in RAW264.7 cells ([Fig. 2A](#f0002){ref-type="fig"}) and increased with centrifugation speed (Fig. S1D). Thus, for the remainder of the study, cells were lysed directly in 8 M urea buffer to avoid losing part of the SQSTM1 pool. Figure 2.DHA induces formation of detergent-resistant SQSTM1/p62-bodies degraded by autophagy and activates NFE2L2. IB of soluble and insoluble fractions of RAW264.7 cells treated with DHA (70 µM) with or without BafA1 (100 nM) for (A) 16 h or (B) 8 h followed by 12 h incubation in fresh medium (Med) with or without BafA1. Hmw SQSTM1 was visualized by long exposure (exp). (C) IB of RAW264.7 cells treated with DHA, OA or AA (70 µM) with or without BafA1 (100 nM) for 8 h. Data are representative of 3 independent experiments. (D) FACS analysis of ROS levels in RAW264.7 cells at different time points after DHA (70 µM) using a fluorescent CM-H2DCFDA probe, n = 3, (paired t-test). (E) Confocal analysis of RAW264.7 cells treated with DHA, OA or AA (70 µM) for 3 h (scale bars: 10 µm). Representative images are shown, n = 3. (F) IB analysis of cytosolic (Cyt) or nuclear (Nuc) fractions after 3 h DHA with or without addition of 5 mM NAC or 6 h DHA and quantification of cytosolic SQSTM1 levels and nuclear NFE2L2 levels (below), n = 3, (repeated-measures ANOVA with Dunnett\'s). (G) IB analysis and quantification (right) of RAW264.7 cells after 3 h DHA with or without addition of 5 mM NAC, n = 3, (repeated-measures ANOVA with Dunnett\'s). (H) IB analysis and quantification (right) of MDM after 3 h DHA with or without addition of 5 mM NAC, n = 3. (I) QRT-PCR analysis of NFE2L2 target genes *SQSTM1*, *HMOX1*, *NQO1* and *SLC7A11* in vehicle- and DHA-treated MDMs, n = 5 (Friedman test with Dunn\'s).

SQSTM1 is continuously turned over by autophagy.[@cit0021] A combined treatment with DHA and the lysosomal inhibitor bafilomycin A~1~ (BafA1) caused an additive increase in the protein level of SQSTM1 in the detergent-resistant fraction. However, no concurrent increase in the protein level of MAP1LC3B was observed after BafA1 treatment ([Fig. 2A](#f0002){ref-type="fig"}). This shows that autophagy can be elevated as measured by the number of SQSTM1 proteins degraded per cell, without affecting the turnover of MAP1LC3B-II. Interestingly, DHA also induced some slower migrating proteins detected by SQSTM1 antibodies in both RAW264.7 cells and MDMs ([Fig. 2A](#f0002){ref-type="fig"} and S1E), which were clearly reduced by siRNA targeting *SQSTM1* (Fig. S1E). The same migration pattern was detected using 5 different SQSTM1-specific antibodies in ARPE-19 cells (Fig. S1F). The 2 most prominent of these additional SQSTM1 bands migrated at approximately 70,000 and 120,000, of which the latter is indicated as high molecular weight (hmw) SQSTM1. Each of the additional bands accounted for approximately 5% of total SQSTM1 levels in DHA- and BafA1-treated cells. The hmw SQSTM1 showed the same concentration- and time-dependent increase as unmodified SQSTM1 (Fig. S1A and S1B), was especially prominent in the detergent-resistant fraction and was strikingly elevated after cotreatment with DHA and BafA1 ([Fig. 2A](#f0002){ref-type="fig"}). Importantly, hmw SQSTM1 could be depleted from the soluble fraction and enriched in the detergent-resistant pellet by increasing centrifugation speed (Fig. S1D). The elevated protein levels of SQSTM1 and hmw SQSTM1 were of a transient nature. Removal of DHA and incubation for an additional 12 h in fresh medium clearly reversed the DHA-induced effects ([Fig. 2B](#f0002){ref-type="fig"}). The reduction in SQSTM1 protein levels could be blocked by adding BafA1 in the recovery medium, suggesting turnover by autophagy. As for the SQSTM1/p62-bodies, hmw SQSTM1 was mainly induced by DHA ([Fig. 2C](#f0002){ref-type="fig"}). Together, these results demonstrate that DHA induces SQSTM1 protein levels, posttranslational modifications and translocation of the protein into detergent-resistant cytoplasmic bodies in a lipid-selective manner. Furthermore, the formed structures are of a transient nature and degraded by autophagy.

The *SQSTM1* gene is induced in response to cellular stress such as reactive oxygen species (ROS) via the transcription factor NFE2L2^23,24^ and ROS are involved in the formation of ALIS.[@cit0022] We have previously found that DHA induced transient ROS and NFE2L2 nuclear translocation in ARPE-19 cells.[@cit0020] Also in macrophages, DHA induced ROS at time points preceding the increase in SQSTM1 protein levels as measured by a fluorescent ROS DCF probe ([Fig. 2D](#f0002){ref-type="fig"}). Nuclear translocation of NFE2L2 could be observed by confocal microscopy ([Fig. 2E](#f0002){ref-type="fig"}) and immunoblotting of cytosolic (Cyt) and nuclear fractions (Nuc) ([Fig. 2F](#f0002){ref-type="fig"}). Consistent with a NFE2L2-mediated anti-oxidative response, the NFE2L2 target protein HMOX1 (heme oxygenase 1) showed a similar increase as SQSTM1 in response to DHA ([Fig. 2G](#f0002){ref-type="fig"}). Both the DHA-induced ROS increase, translocation of NFE2L2 and rise in SQSTM1 and HMOX1 protein levels was strongly reduced by a pretreatment with the ROS scavenger N-acetyl cysteine (NAC) ([Fig. 2D, 2F and 2G](#f0002){ref-type="fig"}). Similarly, in MDMs, HMOX1 protein levels increased in response to DHA, but clearly less so in the presence of NAC ([Fig. 2H](#f0002){ref-type="fig"} and S1C). Importantly, DHA induced the transcriptional activity of NFE2L2 as measured by increased mRNA levels of its target genes *SQSTM1*, *HMOX1*, *NQO1* (NAD\[P\]H quinone dehydrogenase 1) and *SLC7A11* (solute carrier family 7 member 11) in MDMs ([Fig. 2I](#f0002){ref-type="fig"}).

DHA strongly reduced expression of CXCL10 by affecting several signaling pathways {#s0002-0003}
---------------------------------------------------------------------------------

Anti-inflammatory effects of n-3 PUFAs have been determined as reduced induction of diverse pro-inflammatory cytokines. To identify putative anti-inflammatory effects of DHA in our system, we determined if macrophages respond differently to LPS when pretreated with DHA for 16 h. This time point was used because the number of SQSTM1/p62-bodies peaked at this time. As an initial screen, NanoString technology was used to quantify the levels of 579 inflammation-related transcripts in DHA-pretreated MDMs from 2 donors that were stimulated with LPS for 3 h. Of these genes, 163 were selected as LPS-responsive transcripts as their mRNA levels increased more than 1.5-fold in each donor. Among those, 148 were downregulated and 15 upregulated by DHA pretreatment ([Fig. 3A](#f0003){ref-type="fig"} and Table S1). The clearest reduction was seen for *CXCL9, CXCL10* and *CXCL11*, a subfamily of chemokines that are highly inducible by IFNG/IFNγ and signal through their common receptor CXCR3 (C-X-C motif chemokine receptor 3)[@cit0025] to attract additional immune cells. CXCL10 is the best studied of these and is implicated in diseases with underlying inflammation.[@cit0026] Of note, classical NFKB target genes including *TNF* (tumor necrosis factor), *IL1B* (interleukin 1 β) and *IL6*, displayed only minor or opposite changes by DHA pretreatment in this screen. These observations were validated by qRT-PCR as in primary macrophages isolated from 5 different healthy donors, where DHA pretreatment caused an approximately 80% reduction in the LPS-induced expression of *CXCL10* in a lipid selective manner ([Fig. 3B and 3C](#f0003){ref-type="fig"}). The lowered mRNA levels of *CXCL10* were accompanied by reduced secretion of CXCL10 measured by ELISA (Fig. S2A). Also in RAW264.7 macrophages, we observed a significant decrease in the induction of *Cxcl10* but also *Tnf* mRNA after DHA pretreatment and stimulation with LPS for 3 h (Fig. S2B). We thus asked if this difference could be explained by different kinetics of *TNF* induction in both systems. Indeed, in MDMs, DHA pretreatment caused reduction in the LPS induction of *TNF* mRNA levels at earlier time points and was more pronounced at the peak of *TNF* expression at 2 h of LPS stimulation (Fig. S2C). The DHA-mediated decrease in *CXCL10* was not limited to induction by LPS but could also be seen with other inducers of IFN signaling such as TLR3 (toll like receptor 3) ligand poly(p)(I:C) and the synthetic TLR8 ligand pU (Fig. S2D). Overall, these data show that DHA particularly dampens type-I IFN responses, including CXCL10 induction, in a lipid-selective manner in mouse and human macrophages. Figure 3.The n-3 PUFA DHA strongly reduced expression of CXCL10 by affecting several signaling pathways. (A) MDMs were treated with DHA (70 µM) for 16 h before stimulation with LPS (100 ng/ml) for 3 h. Transcript levels of 579 genes (nCounter GX Human Immunology kit assay) were determined. Transcripts that were more than 1.5-times increased by LPS in both donors were selected and the fold change between vehicle- and DHA-treated cells calculated, mean ± SD, n = 2. (B) QRT-PCR analysis of CXCL10 and (C) TNF in MDM treated with DHA, OA or AA for 16 h and LPS for 3 h, n = 5 (Friedman test with Dunn\'s). (D) IB analysis and quantification of IRF3 and RELA phosphorylation in MDMs treated with DHA, OA or AA for 16 h and LPS for 1 h, n = 5. (Friedman test with Dunn\'s), of (E) TBK1, IKBKB, STAT1 and STAT3 phosphorylation in MDMs treated with DHA, OA or AA for 16 h and LPS for 1 or 4 h, n = 5 (Wilcoxon matched-pairs signed rank test, one-tailed) and of (F) IRF1 and RELA in cytosolic (Cyt) and nuclear (Nuc) fractions in MDMs treated with DHA, OA or AA for 16 h and LPS for 2 or 4 h, n = 5 (Wilcoxon matched-pairs signed rank test). (G) *IFNB1* mRNA levels after incubation with DHA for 16 h and LPS for 2 h, n = 6 (Wilcoxon matched-pairs signed rank test).

The synthesis of CXCL10 is regulated at the transcriptional level by the transcription factors NFKB complex, IRF3 (interferon regulatory factor 3), IRF1 and STAT1 (signal transducer and activator of transcription 1).[@cit0027]^,^[@cit0028] To determine which initial signaling axis DHA affects, phosphorylation of IRF3 (S386) and the NFKB subunit RELA/p65 (S536) was analyzed. DHA pretreatment led to reduced levels of phosphorylated IRF3 in response to LPS in MDMs while no change in phosphorylation of RELA (S536) was observed ([Fig. 3D](#f0003){ref-type="fig"}). We also checked subunit NFKB1/p105 (S933) of the heterodimeric NFKB complex, which showed a reduced phosphorylation in response to LPS after DHA pretreatment (Fig. S2E). In RAW264.7 cells, DHA similarly reduced the phosphorylation of IRF3 (S396) and NFKB1 (S933) but not RELA (S536) (Fig. S2F). We then analyzed the phosphorylated, active forms of IKBKB/IKKβ (inhibitor of nuclear factor kappa B kinase subunit β) and TBK1 (TANK binding kinase 1) that are upstream kinases of classical NFKB and IRF3 signaling, respectively.[@cit0029] Surprisingly, in MDMs, DHA pretreatment decreased the LPS-induced levels of phosphorylated IKBKB but not TBK1 ([Fig. 3E](#f0003){ref-type="fig"}).

Besides direct induction via IRF3 and NFKB, *CXCL10* is induced as a secondary response gene in an IFN-dependent manner. After TLR4 stimulation, secreted IFNs bind to IFNAR1 (interferon α and β receptor subunit 1) in an autocrine manner and activate JAK2 (Janus kinase 2)-STAT1 signaling and synthesis of CXCL10.[@cit0030]^,^[@cit0031] We found approximately 50% reduced *IFNB* and *IFNG* mRNA induction after DHA pretreatment in the NanoString data (Table S1), and could confirm limited induction of *IFNB* mRNA 2 h after LPS stimulation in DHA-pretreated MDMs ([Fig. 3G](#f0003){ref-type="fig"}). Moreover, inhibition of IFNAR1 suppressed LPS-mediated CXCL10 induction similarly to DHA and limited further reduction by DHA (Fig. S2G), demonstrating that the n-3 PUFA supplementation also dampened autocrine IFN signaling. Consistently, DHA pretreatment decreased the phosphorylation of both STAT1 and STAT3 when induced by 4 h LPS stimulation; however, this was more pronounced and significant only for STAT3 ([Fig. 3E](#f0003){ref-type="fig"}). Also in RAW264.7 macrophages DHA but not OA or AA pretreatment dampened the activation of STAT1 (Fig. S2F).

Of note, in the mRNA expression screen DHA pretreatment also reduced the LPS induction of *IRF1, IRF4, IRF7* and *IRF8* (Table S1). IRF1 is strongly induced in response to IFN and other cytokines[@cit0032] and binds to the *CXCL10* promotor.[@cit0033] Therefore, we investigated if nuclear translocation of IRF1 is affected by DHA. Immunoblotting showed a clear increase of nuclear IRF1 levels after 2 h and 4 h of LPS stimulation that was clearly reduced in DHA-pretreated MDMs. RELA could also be detected in nuclear lysates after 2 h of LPS stimulation, but was unchanged by DHA-pretreatment ([Fig. 3F](#f0003){ref-type="fig"}). In addition, confocal image analysis showed increased intensity of nuclear IRF1 staining at 2 h of LPS stimulation, which was limited by DHA pretreatment while number, area and maximum radius of SQSTM1/p62-bodies were augmented (Fig. S2I).

The DHA-mediated inflammatory tolerance is related to the formation of SQSTM1/p62-bodies {#s0002-0004}
----------------------------------------------------------------------------------------

The results presented above demonstrate that DHA selectively induced the formation of SQSTM1/p62-bodies or ALIS and reduced LPS-induced CXCL10 expression. To assess the relation between both observations, MDMs were pretreated with DHA for increasing times and finally stimulated with LPS for 1 h. Interestingly, the decrease in phosphorylated IRF3 and IKBKB was clearest when SQSTM1 levels were most induced ([Fig. 4A](#f0004){ref-type="fig"}). Figure 4.The DHA-mediated inflammatory tolerance is related to the formation of SQSTM1/p62-bodies. (A) IB analysis of MDMs treated with DHA (70 μM) for the indicated times followed by LPS for 1 h. The quantification (below) represents mean fold changes ± SEM of DHA + LPS compared to vehicle + LPS on a log scale, n = 6, (Friedman test with Dunn\'s). (B) QRT-PCR analysis of *CXCL10* levels in MDM after 16 h DHA with and without addition of 5 mM NAC followed by 3 h LPS, n = 3, (repeated-measures ANOVA with Dunnett\'s). (C) QRT-PCR analysis of *CXCL10* in *SQSTM1* siRNA-transfected MDMs treated with DHA for 16 h and LPS for 3 h, n = 5, (Friedman test with Dunn\'s). (D) IB analysis of IRF3, RELA and IKBKB phosphorylation in control and SQSTM1 knockdown MDMs, n = 6 (Friedman test with Dunn\'s). (E) CXCL10 protein levels in *Sqstm1^+/+^* (n = 8) and *sqstm1^−/−^* (n = 10) male mice were measured by ELISA. Serum was analyzed at baseline and at 3 and 6 h after challenge with 3.5 µg/g LPS. ND, not detected.

We thus speculated that formation of SQSTM1/p62-bodies could play a role in establishing tolerance towards inflammatory signaling. We first checked if impaired formation of SQSTM1/p62-bodies would impair downregulation of *CXCL10* by DHA. As shown above, the induction of SQSTM1 by DHA could be prevented by adding the anti-oxidant NAC. Treatment with NAC before stimulation with LPS limited CXCL10 induction to a similar extent as DHA alone, showing little further effect of the combination of NAC and DHA ([Fig. 4B](#f0004){ref-type="fig"}). As activation of NFE2L2 might also play a role in this observation, we treated MDMs with L-sulforaphane (L-Sulf), an established activator of NFE2L2. Treatment with L-Sulf abolished LPS-induced CXCL10 expression (Fig. S2H). SQSTM1 is known to be necessary for the formation of ALIS.[@cit0022] Thus we speculated that knockdown of SQSTM1 would interfere with the formation of SQSTM1/p62-bodies and the downregulation of CXCL10 by DHA. SQSTM1 was shown to have anti-inflammatory[@cit0012]^,^[@cit0016]^,^[@cit0034] but also pro-inflammatory effects itself.[@cit0018]^,^[@cit0019] In line with the pro-inflammatory role of SQSTM1, the SQSTM1-depleted MDMs displayed reduced expression of *CXCL10* in response to LPS ([Fig. 4C](#f0004){ref-type="fig"}). SQSTM1-depleted MDMs, also showed decreased levels of phosphorylated IKBKB and IRF3, although not significant for IRF3, and no further decrease by DHA treatment ([Fig. 4D](#f0004){ref-type="fig"}). Similarly, a trend of decreased CXCL10 secretion after 3 and 6 h LPS challenge was observed in *Sqstm1* depleted (*sqstm1*^−/−^) mice ([Fig. 4E](#f0004){ref-type="fig"}), suggesting that SQSTM1 is involved in the induction of CXCL10 signaling in vivo. Together these data indicate that SQSTM1 is necessary for full induction of CXCL10 expression, whereas the formation of SQSTM1/p62-bodies is important for the LPS tolerance induced by n-3 PUFAs like DHA.

KEAP1 is sequestered in DHA-induced SQSTM1/p62-bodies and contributes to inflammatory tolerance {#s0002-0005}
-----------------------------------------------------------------------------------------------

The obtained results indicated that the DHA-mediated formation of SQSTM1/p62-bodies dampened LPS-induced signaling in macrophages. We therefore aimed to characterize the proteins recruited into the DHA-induced SQSTM1/p62-bodies that mediate the tolerance towards inflammatory stimuli.

The previously established centrifugation protocol was used for partial purification of DHA-induced SQSTM1/p62-bodies from RAW264.7 cells and the isolated proteins were identified by mass spectrometry (MS). Proteins were considered as DHA-specifically enriched in the detergent insoluble fraction if they were more abundant in DHA-treated samples versus vehicle as well as further elevated in samples cotreated with DHA and BafA1 versus BafA1 alone. Using these criteria, SQSTM1 was clearly the most abundant DHA- and BafA1-induced protein in the detergent-resistant fraction (Fig. S3A). Interestingly, TAX1BP1 and KEAP1 were the second and third most prominent proteins recruited into the detergent-resistant fraction in response to DHA and clearly further accumulated by inhibiting lysosomal degradation. However, since this analysis was only based on different detergent solubility, the detected proteins could reside in many different compartments and structures. In order to limit the detection of proteins to DHA-induced partners of SQSTM1, we performed immunoprecipitation (IP) of endogenous SQSTM1 from vehicle treated or DHA-stimulated RAW264.7 cells and identified copurified interaction partners by MS (Fig. S3B). KEAP1 and TAX1BP1 were the only proteins that were found both in the detergent-resistant fraction as well as co-immunoprecipitated with SQSTM1 and were thus considered as located to SQSTM1-containing protein bodies in a DHA-induced manner. These interactions were validated in MDMs where KEAP1 and TAX1BP1 co-immunoprecipitated with SQSTM1 ([Fig. 5A](#f0005){ref-type="fig"}). Apparently, DHA did not change the affinity of TAX1BP1 or KEAP1 for SQSTM1 but the association increased proportionally with the lipid-induced rise in SQSTM1 protein level. Figure 5.KEAP1 is sequestered in DHA-induced SQSTM1/p62-bodies and contributes to inflammatory tolerance. (A) IP of SQSTM1 from MDMs treated with DHA for 16 h and IB analysis of KEAP1 and TAX1BP1; INPUT (10%). Data are representative of 3 independent experiments. (B) Immunostaining for SQSTM1 and KEAP1 in MDMs treated with DHA for 24 h (scale bars: 10 µm). (C) IB analysis and quantification (below) of SQSTM1 and KEAP1 in soluble and insoluble fractions from RAW264.7 cells after 16 h DHA, n = 4 (repeated measures ANOVA). (D) QRT-PCR analysis of *CXCL10* or (E) *CXCL11* in KEAP1 siRNA-transfected MDMs treated with DHA for 16 h and LPS for 3 h, n = 5 (Friedman test with Dunn\'s). (right) Comparison of the downregulating effect of DHA in control or *KEAP1* siRNA-treated MDMs from (D) or (E) respectively, n = 5 (Mann Whitney test).

TAX1BP1 is an autophagy receptor involved in xenophagy[@cit0035] and could bind SQSTM1 indirectly via ubiquitin. KEAP1 mediates ubiquitination and degradation of NFE2L2 under normal unstressed conditions[@cit0036] and has been suggested to contribute to degradation of protein aggregates.[@cit0037] Also, the association of KEAP1 with SQSTM1/p62-bodies has been shown to stabilize and activate NFE2L2.[@cit0038] NFE2L2 activation, besides its anti-oxidative function, plays an important role in the regulation of inflammation.[@cit0039] In addition, we recently demonstrated a role for KEAP1 in the regulation of inflammatory signaling, via ubiquitination and degradation of IKBKB.[@cit0043] Intriguingly, TAX1BP1 has been implicated as a negative regulator of NFKB signaling due to the recruitment of the ubiquitin-editing enzyme TNFAIP3.[@cit0044] Also, IRF3-dependent signaling is negatively regulated by TAX1BP1 and TNFAIP3.[@cit0045]^,^[@cit0046] Immunostaining of MDMs demonstrated that both KEAP1 and TAX1BP1 are located in DHA-induced SQSTM1/p62-bodies ([Fig. 5B](#f0005){ref-type="fig"} and S3C). In contrast to MS data and IPs, by confocal analysis also TNFAIP3 could be detected in SQSTM1/p62-bodies (Fig. S3C) indicating that this protein interacts with the SQSTM1/p62-bodies in a more transient manner. Importantly, about 20% of KEAP1 was found in insoluble aggregates and corresponded well with the fraction of SQSTM1 that translocated to the detergent-resistant fraction in response to DHA treatment ([Fig. 5C](#f0005){ref-type="fig"}). As the sequestration of KEAP1 by SQSTM1 has previously been shown to lead to NFE2L2 activation, we analyzed the mRNA level of *NQO1* in SQSTM1 knockdown cells treated with LPS and DHA. In line with an important role of SQSTM1 in activation of NFE2L2 in the presence of DHA, *NQO1* mRNA (as opposed to CXCL10) was significantly induced by DHA in a SQSTM1-dependent manner (Fig. S3D).

We next asked if recruitment of KEAP1, TAX1BP1 or TNFAIP3 into SQSTM1/p62-bodies has a repressive function on CXCL10 signaling. MDMs were transfected with siRNA targeting *KEAP1, TAX1BP1* and *TNFAIP3* and decreased protein or mRNA levels were observed, albeit TNFAIP3 was less efficiently reduced (Fig. S3E, S3F). As KEAP1 is the repressor of NFE2L2, the expression of NFE2L2 target genes was analyzed in KEAP1-depleted MDMs and showed at least partial activation of NFE2L2 with induction of *NQO1* and *SLC7A11* (Fig. S3G). Depletion of *TAX1BP1* or *TNFAIP3* did not have any significant effect on *CXCL10* levels (Fig. S3H and S3I), whereas depletion of KEAP1 significantly limited the ability of DHA to dampen LPS-induced *CXCL10* expression ([Fig. 5D](#f0005){ref-type="fig"}). When directly comparing the reduction by DHA-pretreatment on LPS-induced CXCL10 expression, there was a significant difference in the presence or absence of KEAP1 (76.4% ± 16.4% vs 44.8% ± 22.2% respectively, with less effective DHA pretreatment in KEAP1-depleted cells in all 5 replicates) ([Fig. 5D](#f0005){ref-type="fig"}, right). The same pattern could be seen for mRNA induction of *CXCL11* ([Fig. 5E](#f0005){ref-type="fig"}), another chemokine strongly affected by DHA. Thus, the formation of SQSTM1/p62-bodies and sequestration of KEAP1 plays a role in the DHA-mediated inflammatory tolerance in macrophages.

The plasma level of CXCL10 is reduced by n-3 PUFA supplementation but increased in the placebo group in hypertensive heart transplant recipients. {#s0002-0006}
-------------------------------------------------------------------------------------------------------------------------------------------------

According to our results, we expected n-3 PUFA supplementation to be most effective in conditions with chronically elevated CXCL10 levels. Therefore, we obtained plasma samples of the heart transplant patients in the OmaCor-study, as elevated levels of CXCL9 and CXCL10 are known as causes for transplant rejection.[@cit0047]^,^[@cit0048] Plasma samples of these patients were taken at baseline after transplantation and following 12 mo with daily administration of n-3 PUFA (DHA and eicosapentaenoic acid) or placebo (corn oil). This clinical trial documented an improved clinical outcome from intake of n-3 PUFAs compared to the placebo group as measured for example by lowered blood pressure.[@cit0049] However, a corresponding reduction in any inflammatory mediators in response to the n-3 PUFAs have not been previously found. In fact, TNF was slightly increased by n-3 PUFA treatment in this study.[@cit0050] We measured CXCL10 by ELISA on those patient plasma samples and found the CXCL10 levels in the placebo group increased after transplantation in line with a nonresolved inflammation in these patients. Conversely, in total agreement with the results from the cell-based assays, n-3 PUFA administration significantly decreased CXCL10 levels after transplantation ([Fig. 6](#f0006){ref-type="fig"}, left). In line with our expression analyses, the IL6 levels did not differ between the placebo and the n-3 PUFA group ([Fig. 6](#f0006){ref-type="fig"}, right). These data suggest that n-3 PUFA supplementation dampens conditions driven by sterile inflammation and that a reduced type-I interferon response, including lowered CXCL10, represents potent markers for such beneficial effects. Figure 6.The plasma level of CXCL10 is reduced by n-3 PUFA supplementation but increased in the placebo group in hypertensive heart transplant recipients. The concentration of CXCL10 (left) and IL6 (right) was determined by ELISA in plasma of hypertensive heart transplant recipients isolated at baseline and after 12 mo of daily supplementation of placebo (corn oil, n = 19) or n-3 PUFAs (n = 16). Horizontal lines represent mean plasma levels. p \< 0.01, p \< 0.05 and nonsignificant (n.s.) were all vs baseline.

To relate this observation to our in vitro mechanism, we wanted to assess NFE2L2 activation in our patient material. *IL36G* is a direct target gene of NFE2L2 and upregulated by NFE2L2 activation.[@cit0051] We measured IL36G levels as read-out for NFE2L2 and found an inverse correlation between CXCL10 and IL36G levels at baseline (r = -0.57, p \< 0.05), suggesting that NFE2L2 activity contributes to limit CXCL10 levels (data not shown).

In summary, our data are consistent with an important role of DHA-induced SQSTM1 polymerization and resulting NFE2L2 activation in the reduction of serum levels of CXCL10.

Discussion {#s0003}
==========

With increasing evidence of the health benefits and anti-inflammatory effects of n-3 PUFAs, these lipids represent a valuable tool to identify cellular mechanisms of maintenance and homeostasis. In response to polyunsaturated fatty acids, we found that macrophages dampened pro-inflammatory signaling as evident by reduced transcription of a large number of inflammation-related genes after LPS stimulation. The effects were clearest for type-I IFN-related responses with CXCL10 as the most prominent. Importantly, CXCL10 protein levels were reduced both in the media of cultured macrophages and in blood samples of patients supplemented with n-3 PUFAs. We found that SQSTM1/p62-bodies, protein bodies containing the autophagic cargo receptor SQSTM1, are formed in response to the n-3 PUFA DHA. The ROS sensor KEAP1, the autophagy receptor TAX1BP1 and the ubiquitin-editing enzyme TNFAIP3 could be found in SQSTM1/p62-bodies. Of these proteins, depletion of KEAP1 led to limited effects of DHA supplementation. We suggest that the DHA-mediated formation of SQSTM1/p62-bodies and recruitment of KEAP1 represent a fast mechanism for NFE2L2 activation, playing a role in the regulation of inflammatory signaling in macrophages. Thus, the data point to an important balance where dietary lipids influence endogenous and exogenous antioxidants in controlling inflammatory signaling in macrophages.

SQSTM1 is known to form aggregates and to sequester ubiquitinated proteins into speckles also described as ALIS.[@cit0021] These structures were initially shown in dendritic cells during maturation[@cit0052] and may occur in response to various cellular stresses such as LPS stimulation, infection, oxidative stress or proteasomal inhibition.[@cit0053] DHA supplementation led to a transient increase in detergent-resistant SQSTM1/p62-bodies associated with ubiquitinated proteins. Sequestration of potentially harmful and misfolded proteins might help in detoxification of the cytoplasm and could disarm inflammation-prone conditions. Interestingly, Sergin et al. reported a protective role of SQSTM1 in the sequestration of ubiquitinated inclusions in atherosclerosis, as deletion of the gene encoding SQSTM1 caused diffuse distribution of ubiquitinated and misfolded proteins and had worse outcomes.[@cit0054]

ALIS are reported to be degraded via the autophagic-lysosomal pathway.[@cit0008]^,^[@cit0022] The increase in SQSTM1/p62-bodies observed after DHA supplementation was transient and reversible in case of functional autophagosome-lysosome fusion, indicating that DHA-induced SQSTM1/p62-bodies are handled via lysosomal degradation. Further, our results suggest that the autophagic clearance of tightly packed protein speckles of SQSTM1 and associating proteins can be elevated without any major changes in basal autophagy as measured by the turnover of MAP1LC3B-II. SQSTM1 can homopolymerize[@cit0055] and 1 molcule of MAP1LC3B likely intereacts with a chain of SQSTM1.[@cit0008] Thus, the autophagic turnover of SQSTM1 may increase by stimuli that increase polymerization without any detectable change in MAP1LC3B degradation. How homopolymerization of SQSTM1 is regulated represents an interesting question as the ability of cargo receptors to polymerize may be an important regulatory step for autophagy. In this regard, we observed posttranslational modifications of SQSTM1, as seen by slower migrating protein forms in response to n-3 PUFA supplementation. SQSTM1 can form covalently crosslinked oligomers in response to ROS-inducing drugs in a PB1-dependent manner.[@cit0056] We find that DHA stimulates the formation of hmw SQSTM1, which might be explained by the generation of ROS or direct crosslinking of SQSTM1 as DHA is a highly reactive and easily oxidized molecule.[@cit0057] Also, a transient increase in hmw SQSTM1 as well as activation of NFE2L2 has been reported for other PUFAs.[@cit0058] Thus, covalent crosslinking of SQSTM1 dimers can be an important mode of regulation of protein turnover after oxidative stress also under noncytotoxic conditions. Also our data indicate that crosslinked SQSTM1 in protein aggregates mediates a transient storage of damaged proteins that are degraded by autophagy after new synthesis of unmodified SQSTM1. On the contrary, diets containing already oxidized n-3 PUFAs increase inflammatory signaling,[@cit0059] suggesting that the original reactivity of the molecule might be needed for beneficial effects. In this regard, a balanced level of exogenous anti-oxidants in the n-3 PUFA formulation seems important to prevent oxidation of the lipid but also allow activation of endogenous anti-oxidative responses.

We observed activation of NFE2L2 with coinciding induction of its target genes *SQSTM1, HMOX1, NQO1* and *SLC7A11* during DHA treatment in total agreement with what we recently reported also in nontransformed, diploid epithelial cells.[@cit0020] The interaction of SQSTM1 and KEAP1 and the sequestration of KEAP1 into SQSTM1/p62-bodies has been shown as an alternative way to liberate and activate NFE2L2.[@cit0060]^,^[@cit0061] We here describe the formation of SQSTM1/p62-bodies with sequestration of a substantial fraction of KEAP1 in response to the physiological stimuli DHA as a fast mechanism for NFE2L2 activation. In this line, depletion of SQSTM1 or KEAP1 modulated NFE2L2 activation and impaired the DHA-mediated anti-inflammatory effects. NFE2L2 has been firmly established as a regulator of inflammation.[@cit0040]^,^[@cit0062] We found that activation of NFE2L2 by an established inducer strongly limited LPS-induced CXCL10 expression. *nfe2l2* knockout mice show increased mortality and inflammatory markers such as phosphorylated IRF3 during septic shock,[@cit0041] including augmented expression of CXCL10.[@cit0039] In humans, NFE2L2 polymorphisms are associated with the development of gastric mucosal inflammation[@cit0063] and increased risk for acute lung injury characterized by inflammation.[@cit0064] Also, NFE2L2 and expression of HMOX1 have been implicated in the development of a macrophage phenotype with lower inflammatory signature.[@cit0042]^,^[@cit0065]^,^[@cit0066] Finally, in *nfe2l2* knockout mice, the anti-inflammatory effects of DHA have been shown to be NFE2L2-dependent.[@cit0067]

Interestingly, exposure to LPS has not only been found to induce ALIS, but also to establish endotoxin tolerance, limiting further inflammatory signaling in septic patients[@cit0068] and monocytes.[@cit0069] In addition, Vasconcellos et al. recently demonstrated that free heme and iron, as a result of hemolysis, induce ALIS as a way to maintain homeostasis.[@cit0070] These reports suggest that under physiological conditions transient formation of SQSTM1/p62-bodies could represent a beneficial mechanism of NFE2L2 activation. Of interest, a role of KEAP1 in the clearance of SQSTM1/p62-bodies has been reported[@cit0037] while CXCL10 secretion is increased in autophagy-deficient cells.[@cit0071] Thus, the presence of KEAP1 in SQSTM1/p62-bodies might promote their autophagic degradation, limiting CXCL10 expression. Furthermore, we have previously shown that KEAP1 dampens inflammatory signaling by degradation of IKBKB in mycobacterial infection,[@cit0043] thus KEAP1 might have additional NFE2L2-independent ways of regulating inflammation.

Anti-inflammatory effects of n-3 PUFAs have been established on the expression of many cytokines, but differ between model systems. By taking a broad approach to screen for quantitative differences of more than 500 inflammation gene products, we could identify CXCL10 as the most clearly dampened cytokine after n-3 PUFA treatment. This cytokine was consistently lowered at both the mRNA level and as a secreted protein in mouse macrophages, primary human macrophages and in heart transplant patients in a lipid-selective manner. Increased intake of DHA has been found to reduce the level of CXCL10 in vivo in a mouse model of stress-induced dry eye.[@cit0072] Also, n-3 PUFA supplementation decreases the CXCL10 concentration in hepatitis C patients.[@cit0073] Of note, one clinical trial suggested that n-3 PUFAs from flaxseed augment the expression of NQO1 in cystic fibrosis patients,[@cit0074] making it possible to speculate that the formation of SQSTM1/p62-bodies and activation of NFE2L2 as we have shown in macrophages might also play a role to limit CXCL10 during clinical DHA supplementation. This is further supported by the inverse correlation that we found in our patient samples between CXCL10 and the NFE2L2-controlled cytokine IL36G.[@cit0051] Importantly, we here show lowered CXCL10 levels to correlate with the better clinical outcome seen in n-3 PUFA-supplemented heart transplant patients. This study used an n-3 PUFA formulation with the minimum of exogenous anti-oxidants. Our data show that exogenous anti-oxidants can interfere with the activation of the anti-oxidative response by DHA and might thus prevent beneficial health effects. Patients with cardiovascular diseases, inflammatory disorders, microbial pathologies and Alzheimer disease also have increased CXCL10 levels as a consequence of persistent inflammation.[@cit0026]^,^[@cit0075] Thus, CXCL10 might be a useful marker for anti-inflammatory effects of n-3 PUFAs in these pathological conditions.

In summary, we identify CXCL10 as a robust marker for the inflammatory tolerance established by n-3 PUFAs in clinical settings with low-grade chronic inflammation. We propose that lipid-induced transient activation of the cellular stress response, as seen by activation of NFE2L2 by formation of SQSTM1/p62-bodies with association of KEAP1, counteracts the signals that drive the type-I interferon response and in particular the synthesis of CXCL10. The identified effects of n-3 PUFAs on interferon signaling contribute to our understanding of how the risk of inflammation- and age-related diseases can be modulated by dietary lipids.

Materials and methods {#s0004}
=====================

Cell culture and stimulation {#s0004-0001}
----------------------------

RAW264.7 macrophages (ATCC, TIB71) were cultured in RPMI (Sigma, R8758) with 10% fetal bovine serum (Gibco, 10270--106) and gentamicin (0.05 mg/mL; Gibco, 15710049). ARPE-19 (ATCC, CRL-2302) were cultured in DMEM:F12 (Sigma, D8437). PBMC were isolated from buffy coats (obtained from the blood bank of St. Olavs Hospital, Trondheim, Norway) by a Lymphoprep™ (AXIS-SHIELD PoC AS, 1114547) density gradient. Monocytes were selected by plastic adherence and differentiated into monocyte-derived macrophages (MDM) by culture in RPMI with 30% human serum for 5 d, followed with 10% human serum during experiments. All cells were maintained in 5% CO~2~ at 37°C.

Docosahexaenoic acid (DHA; Cayman, 90310), oleic acid (OA; Cayman, 90260) and arachidonic acid (AA; Cayman, 90010) were added to prewarmed complete medium (70 µM) before being given to the cells. Absolute ethanol was used as control in all experiments.

Other reagents used were: bafilomycin A~1~ (BafA1; Sigma, B1793), LPS (InvivoGen, tlrl-3pelps), L-sulforaphane (L-Sulf; Sigma-Aldrich, S6317), pU complexed with pL-Arg (Sigma Aldrich, P7762) at a 1:1 ratio (w:w), p(I:C) transfected with Lipofectamine RNAiMAX (Invitrogen, 13778150), and N-acetyl-cysteine (NAC; Sigma, A9165).

Antibodies used were: ATCB/β actin (Abcam, ab6276); COX4I1/COXIV (Abcam, ab33985); GAPDH (Merck Millipore, CB1001); HMOX1 (Enzo Life Sciences, ADI-OSA-110); IRF3 (Santa Cruz Biotechnology, sc-9082); KEAP1 (Proteintech, 10503--2-AP); KEAP1 (Santa Cruz Biotechnology, E20); LMNA/lamin A/C (Santa Cruz Biotechnology, sc-6215); mono- and polyUb conjugates (FK2; Biomol, PW8810); SQSTM1 (Progen, GP62-C); phospho-IRF3 (S386; Abcam, ab76493); STAT1 (BD Biosciences, 610116); TNFAIP3/A20 (Santa Cruz Biotechnology, sc-166692). The following were from Cell Signaling Technology: IKBKB/IKKβ (8943); IRF1 (4302); IRF3 (4302S), MAP1LC3B (3868); MAPK1/3/p44/42 (9107); RELA/p65 (3034); phospho-CHUK/IKBKB/IKKα/β (S176/180; 2697); phospho-IRF3 (S396; 4302); phospho-NFKB2/p105 (S933; 4806); phospho-RELA/p65 (S536; 3033); phospho-STAT1 (Y701; 7649); phospho-STAT3 (Y705; 9145); phospho-TBK1 (S172; 5483); STAT1 (14994); STAT3 (9139); TAX1BP1 (5105); TBK1 (3013). For IP of SQSTM1 MBL antibody (PM045) was used and as control guinea pig IgG (Santa Cruz Biotechnology, sc-2711). To inhibit IFNAR1 signaling, anti-IFNAR2/interferon-α/β receptor chain 2 (Merck Millipore, MAB1155) was used. SQSTM1 antibodies used in Fig. S1G were from: BD (610832), Santa Cruz Biotechnology (sc-28359), Abnova (H00008878-M03), Abcam (ab31782) and Progen (GP62-C). All secondary antibodies were from Invitrogen (Alexa Fluor conjugates; A32723, A32727, A32732, A32731, A-11073, A-21435), Li-Cor Biotechnology (NIR dye conjugates; 925--68070, 925--68071, 925--68074, 925--32210, 925--32211, 925--32411, 925--68077) or Dako (HRP conjugates; P0448, P0447).

### ROS detection {#s0004-0001-0001}

Cell were stained with 0.4 µM of the ROS-sensitive probe CM-H2DCFDA (Invitrogen, C6827) for 30 min at 37°C and mean fluorescence was analyzed by a BD FACS Canto (BD Biosciences, San Jose, CA, USA). Experiments were performed in duplicates with 10,000 cells per condition.

### Quantitative real-time PCR (qRT-PCR) {#s0004-0001-0002}

Total RNA was isolated by using the RNeasy kit (Qiagen, 74106). Total RNA (1 µg) was used for cDNA synthesis with the High-Capacity RNA-to-cDNA Kit (Applied Biosystems, 4387406). Real-time PCR was performed using PerfeCTa qPCR FastMix ROX (Quanta, QUNT95077--012) and TaqMan® Gene Expression Assays (Applied Biosystems). The cycling conditions for the StepOne plus system (Applied Biosystems) were 45°C for 2 min, 95°C for 30 sec, 40 cycles of 95°C for 1 sec, 60°C for 20 sec. The following probes were used: *CXCL10* (Hs01124251_g1), *Cxcl10* (Mm00445235_m1), *CXCL11* (Hs04187682_g1), *IFNB1* (Hs01077958_s1), *TNF* (Hs01113624_g1), *Tnf* (Mm00443260_g1), *GAPDH* (Hs99999905_m1), *Gapdh* (Mm99999915_g1), *KEAP1* (Hs00202227_m1), *SQSTM1* (Hs00177654_m1), *HMOX1* (Hs01110250_m1), *NQO1* (Hs00168547_m1) and *SLC7A11* (Hs00921938_m1). Relative mRNA levels were transformed into linear form by the 2(-ΔΔCt) method.[@cit0076] Transcripts were normalized to *GAPDH*.

### Nanostring {#s0004-0001-0003}

Total RNA was extracted and mRNA transcripts were assessed by digital transcript counting (nCounter GX Human Immunology kit assay, NanoString Technologies, Seattle, WA, USA). Total RNA (100 ng) was assayed on nCounter Digital Analyzer (NanoString) according to the manufacturer\'s instructions. Data were normalized by scaling with the geometric mean of the built-in control gene probes for each sample.

### Immunoblotting {#s0004-0001-0004}

For total protein extracts, 8 M urea lysis buffer was used (8 M urea, 0.5% \[v:v\] Triton X-100 \[Sigma-Aldrich, X100\], DTT \[100 mM\], Complete® protease inhibitor \[PI; Roche, 11873580001\]), long with phosphatase inhibitor cocktail (PIC) 2 and 3 (Sigma, P5726 and P0044). Protein concentration was determined by Bio-Rad protein assay (Bio-Rad 500--0006). Proteins (50 µg) were separated using NuPAGE® Novex® Bis-Tris Gels (Invitrogen, NP0322, NP0321, WG1403, WG1402A), transferred to nitrocellulose membranes using Invitrogen\'s iBlot system. Bound antibodies were imaged using appropriate near-infrared (NIR) dye conjugates (Li-Cor) and an Odyssey NIR scanner (Li-Cor Biosciences) or using HRP-linked secondary antibodies (Dako) and SuperSignal West Femto substrate (Pierce, 34096) with a Li-Cor Odyssey Fc System. Image studio 3.1 was used for quantification. For statistical assessment, mean intensity values were used, while bar graphs of quantifications show fold changes.

Soluble and insoluble fractions {#s0004-0002}
-------------------------------

Cells were lysed in a detergent buffer (NP-40 \[1%; Calbiochem, 492018\], Triton X-100 \[0.25%; Sigma-Aldrich, X100\], 0.05 M Tris-HCl, 0.15 M NaCl, 0.001 M EDTA, PI, PIC2 and 3) and lysates cleared by centrifugation (1000 g, 10 min). Supernatants were centrifuged at 10,000 g for 20 min and the new supernatant collected (soluble fraction). The detergent-resistant pellet was washed twice and finally resuspended in 8 M urea lysis buffer (insoluble fraction).

### Nuclear extraction {#s0004-0002-0001}

Cells were lysed in a hypotonic buffer containing 10 mM HEPES, pH 7.4, 1.5 mM MgCl~2~, 10 mM KCl, 0.5 mM DTT, 0.1% NP-40, PI, and PIC2 and 3. Lysates were kept on ice, vortexed for 15 min and centrifuged at 3000 g for 10 min. The nuclear pellet was washed once and finally resuspended in 8 M urea lyis buffer. Cytoplasmic extracts were added to 20% 8 M urea buffer.

### Immunostaining {#s0004-0002-0002}

The cells were fixed in 4% formaldehyde, permeabilized with methanol, blocked with 3% goat-serum (Sigma-Aldrich, G9023) and stained with primary and fluorescently labeled secondary antibodies (Alexa Fluor conjugates, Invitrogen). Nuclear DNA was stained using Draq5 (5 µM; Biostatus, DR50200) or Hoechst 33342 (5 µg/ml; Life Technologies, C10337). Imaging was done on an Axiovert200 microscope with a 63 × 1.2W objective and the confocal module LSM510 META (Carl Zeiss). Images were processed using the ZEN software (Zeiss) and mounted using Canvas 11 (Deneba).

### ScanR automated image acquisition {#s0004-0002-0003}

The microscope-based imaging platform ScanR (Olympus, Hamburg, Germany) was used to image SQSTM1/p62-bodies. Images were taken with a 20x objective, using the excitation filters (wavelength \[nm\]/width \[nm\]): FITC (485/20), Alexa Fluor 647 (640/30) and Hoechst (650/13). For emission, a combination filter (440/521/607/700) was used for all fluorophores (Chroma Technology Corp, Bellows Falls, VT, USA). The images were analysed by the ScanR Analysis software (Olympus).

### Small interfering RNA {#s0004-0002-0004}

MDMs were transfected at d 5 and d 7 using Lipofectamine RNAiMAX (Invitrogen, 13778150) using 20 nM siRNA or nontargeting oligo. The following smartpool siRNA oligonucleotides were obtained from Dharmacon: nontargeting (D-001210--01), SQSTM1 (J-010230--06), TAX1BP1 (L-016892--00), TNFAIP3 (L-009919--00) and KEAP1 (LQ-012453--00).

ELISA {#s0004-0003}
-----

CXCL10 in supernatants and serum was quantified using an ELISA Duo-Set (DY266 \[human\] or DY466 \[murine\], R&D, Abingdon, UK) according to the manufacturer\'s instruction. IL36G in serum was quantified using a human IL-36G/IL-1F9 ELISA Kit (EHIL36G, Thermo Scientific).

### IP and mass spectrometry (MS) analyses {#s0004-0003-0001}

For Santa Cruz Biotechnology, Dynabeads protein A (Life Technologies, 10002D) were incubated with antibodies for 1 h at room temperature and complexes were crosslinked with BS[@cit0003] (Life Technologies, 21580) according to the manufacturer\'s protocol. Cells were lysed in a buffer containing 0.25% TX-100, 1% NP-40, 50 mM Tris-HCl, pH 8, 150 mM NaCl, 1 mM EDTA, pH 8, PI, PIC 2 and 3. Lysates were adjusted for concentration and volume and immunoprecipitated at 4°C overnight. Beads were washed 3 times with 400 mM KCl and eluted with LDS sample buffer (Invitrogen, NP0007) at 80°C. For MS, eluates were run into NuPAGE® Gels and stained with SimplyBlue SafeStain (Life Technologies, LC6060). Gel pieces were subjected to in-gel reduction, alkylation, and tryptic digestion using 6 ng/μl trypsin (Promega, V511A).[@cit0077] OMIX C18 tips (Varian, Inc., Palo Alto, CA, USA) were used for sample clean up and concentration. Peptide mixtures containing 0.1% formic acid were loaded onto a Thermo Fisher Scientific EASY-nLC1000 system and EASY-Spray column (C18, 2 µm, 100 Å, 50 µm, 15 cm). Peptides were fractionated using a 2--100% acetonitrile gradient in 0.1% formic acid over 50 min at a flow rate of 250 nl/min. The separated peptides were analyzed using a Thermo Scientific Q-Exactive mass spectrometer. Data were collected in data-dependent mode using a Top10 method. The raw data were processed using the Proteome Discoverer 1.4 software. The fragmentation spectra were searched against the Swissprot SwissProt_2011_12 database using an in-house Mascot server (Matrix Sciences, UK). Peptide mass tolerances used in the search were 10 ppm, and fragment mass tolerance was 0.02 Da. Peptide ions were filtered using a false discovery rate set to 5% for peptide identifications.

Animals {#s0004-0004}
-------

Protocols were approved by the Washington University Animal Studies Committee. Mice used in this study were in the C57BL/6 background and housed in a specific pathogen-free barrier facility. *sqstm1^−/−^* mice were as described previously.[@cit0054]^,^[@cit0078]

Patients {#s0004-0005}
--------

Thirty-five clinically stable hypertensive heart transplant recipients were studied 1--12 y after transplantation and randomized in a double-blind fashion to receive either 3.4 g of omega-3 fatty acids daily or placebo (corn oil) for one y in the OmaCor-study.[@cit0049]^,^[@cit0050] Plasma was sampled for cytokine analyses after overnight fasting at baseline and after 12 mo. The study was approved by the Regional Ethics Committee and all patients gave written informed consent for participation.

Statistical analysis {#s0004-0005-0001}
--------------------

Statistical analyses were performed in Prism 6 (Graph pad). Values are expressed as mean ± standard error of the mean (SEM) if not otherwise stated. Statistical analyses were performed on mRNA fold changes compared to vehicle or on intensities obtained by densitometry of immunoblots, confocal images or FACS analysis. Data from primary cells was analyzed by nonparametric tests where possible; data from cell lines was logtransformed and analyzed by parametric tests as indicated. Coefficients of correlation (r) were calculated using the Spearman\'s rank test. *P*-value \< 0.05 was considered statistically significant and is labeled with \*, and *p* \< 0.01 is labeled with \*\*, *p* \< 0.001 labeled with \*\*\*.

Ethics statement {#s0004-0006}
----------------

The Regional Committees for Medical and Health Research Ethics at the Norwegian University of Science and Technology (NTNU) approved the use of PBMCs from healthy adult blood donors after informed consent (identification number 2009/2245--2). All donors provided written informed consent.
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Abbreviations
=============

AA

:   arachidonic acid

ACTB

:   actin β

ALIS

:   aggresome-like induced structures

ATG8

:   autophagy-related 8

BafA1

:   bafilomycin A~1~

CHUK/IKKα

:   conserved helix-loop-helix ubiquitous kinase

COX4I1

:   cytochrome c oxidase subunit 4I1

CXCL10

:   C-X-C motif chemokine ligand 10

DHA

:   docosahexaenoic acid

DUB

:   deubiquitinating enzyme

FFAR4/GPR120

:   free fatty acid receptor 4

GAPDH

:   glyceraldehyde-3-phosphate dehydrogenase

HMOX1

:   heme oxygenase 1

IB

:   immunoblot

IFN

:   interferon

IFNAR1

:   interferon α and β receptor subunit 1

IKBKB/IKKβ

:   inhibitor of nuclear factor kappa B kinase subunit β

IP

:   immunoprecipitation

IRF

:   interferon regulatory factor

KEAP1

:   kelch like ECH associated protein 1

LIR

:   light chain 3 (LC3)-interacting region

LMNA

:   lamin A/C

LPS

:   lipopolysaccharide

MAP1LC3B

:   microtubule associated protein 1 light chain 3 β

MAPK1/ERK2

:   mitogen-activated protein kinase 1

MAPK3/ERK1

:   mitogen-activated protein kinase 3

MDM

:   monocyte-derived macrophages

n-3 PUFA

:   omega-3 polyunsaturated fatty acid

NAC

:   N-acetylcysteine

NFE2L2/NRF2

:   nuclear factor, erythroid 2 like 2

NFKB

:   nuclear factor kappa B

NFKB2/p105

:   nuclear factor kappa B subunit 2

NQO1

:   NAD(P)H quinone dehydrogenase 1

OA

:   oleic acid

PCNA

:   proliferating cell nuclear antigen

PIC

:   phosphatase inhibitor cocktail

RELA/p65

:   RELA proto-oncogene, NF-kB subunit

p(I:C)

:   poly I:C

ROS

:   reactive oxygen species

RPE

:   retinal pigment epithelium

SLC7A11/xCT

:   solute carrier family 7 member 11

SQSTM1/p62

:   sequestosome 1

STAT1

:   signal transducer and activator of transcription 1

TAX1BP1

:   Tax1 binding protein 1

TBK1

:   TANK binding kinase 1

TLR4

:   toll like receptor 4

TNFAIP3/A20

:   TNF α induced protein 3

TNF

:   tumor necrosis factor

Ub

:   ubiquitin

UBA

:   ubiquitin-associated domain
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